By applying both traditional statistical approaches and AI-enabled interrogation, we demonstrate that the prevalence, spectrum, and treatment associations of PI3K pathway alterations differ substantially between H/L and NHW patients, highlighting the heterogeneity of CRC biology across high-risk groups. The gene discussed is PIK3CA; the disease is colorectal carcinoma.